21/04/2017 12:30:00

Repligen to Report First Quarter 2017 Financial Results

Related content
31 May - 
Repligen to Present at Jefferies’ 2017 Global Annual He..
24 May - 
Repligen to Participate in 14th Annual Craig-Hallum Ins..
09 May - 
Repligen to Present at Bank of America Merrill Lynch 20..

WALTHAM, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter of 2017 financial results on Thursday, May 4, 2017. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the reporting periods ended March 31, 2017. 

The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 11424546. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 11424546. 

About Repligen Corporation

Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the interconnected phases of the biological drug manufacturing process. Our portfolio includes protein products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and filtration products (XCell™ ATF Systems, TangenX™ Sius™ TFF cassettes). Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. The Protein A ligands and growth factor products that we manufacture are components of chromatography resins and cell culture media, respectively. We are the leading manufacturer of Protein A ligands, a critical component of Protein A resins that are the industry standard for downstream separation and purification of monoclonal antibody-based therapeutics. Our growth factors are used in upstream processes to accelerate cell growth and productivity. Our innovative line of OPUS® chromatography columns, used in downstream processes for bench-scale through clinical-scale purification needs, are delivered pre-packed with our customers' choice of resin and bed height. Our XCell™ ATF Systems, available in stainless steel and single-use configurations, continuously eliminate waste from a bioreactor to concentrate cells and increase productivity in upstream processes. Single-use Sius™ TFF cassettes and hardware are used for biologic drug concentration in downstream processes. Repligen's corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Shrewsbury, MA, Lund, Sweden and Weingarten, Germany. 

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Contact:

Sondra Newman

Senior Director Investor Relations

(781) 419-1881

snewman@repligen.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Alliance Trust PLC : Transaction in Own Shares

14/06/2017 07:00:13
14 June 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 13 June 2017 the Company pu..

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

13/06/2017 15:20:46
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECU..

Quarterly Update for the Quarter to 30 April 2017

13/06/2017 12:50:10
13 June 2017 ICG Enterprise Trust Plc Quarterly Update For the quarter to 30 April 2017 Highlights Shar..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
ST announces (i) a US$1.5 billion dual-tranche offering of New Convertible Bonds, (ii) the early redemption of its 2019 Convertible Bonds and (iii) the launch of a share buy-back programme
2
The Plexus Groupe salutes the 2017 EY Entrepreneur of the Year© Midwest award winners
3
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
4
Amundi announces the upcoming completion of the acquisition of Pioneer Investments and presents its future organisation
5
Income Inequality Is Strongly Linked to How Well Countries Convert Wealth into Well-Being

Related stock quotes

Repligen Corporation 40.09 0.6% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 June 2017 02:50:12
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170621.1 - EUROWEB1 - 2017-06-23 03:50:12 - 2017-06-23 02:50:12 - 1000 - Website: OKAY